"Valine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.
| Descriptor ID |
D014633
|
| MeSH Number(s) |
D12.125.070.950 D12.125.142.930
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Valine".
Below are MeSH descriptors whose meaning is more specific than "Valine".
This graph shows the total number of publications written about "Valine" by people in this website by year, and whether "Valine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 9 | 38 | 47 |
| 2018 | 3 | 30 | 33 |
| 2019 | 1 | 6 | 7 |
| 2020 | 1 | 2 | 3 |
| 2021 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Valine" by people in Profiles.
-
Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. J Med Virol. 2021 12; 93(12):6750-6759.
-
V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. J Virol. 2021 07 26; 95(16):e0061721.
-
Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther. 2022 02; 20(2):291-295.
-
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021 Oct; 54(5):767-775.
-
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. J Antimicrob Chemother. 2021 06 18; 76(7):1874-1885.
-
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother. 2021 02 11; 76(3):753-757.
-
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. J Antimicrob Chemother. 2021 01 19; 76(2):286-291.
-
Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials. Theranostics. 2021; 11(3):1207-1231.
-
Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis. J Infect. 2021 04; 82(4):e34-e35.
-
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020 11 01; 75(11):3379-3385.